Sanofi, Translate Bio start seasonal mRNA flu vaccine trial, gaining early lead over Moderna and Pfizer Blackstone, Cellex and Intellia form $250M CAR-T startup Moove over IPO: SAB Biotherapeutics to milk the stock market via SPAC Sponsored: Addressing Roadblocks in Decentralized Clinical Trials TRexBio has Jurassic day picking up ex-Lilly VP as CEO, snagging Big Pharma funding Sponsored: Culture Drives Employee Engagement, Supports Business Growth Alchemab's new well-connected CEO will lead biotech on journey to address hard-to-treat diseases Insilico Medicine scores $255M venture round to move AI-designed drugs into human clinical trials Featured Story | By Nick Paul Taylor Sanofi and Translate Bio have started a phase 1 clinical trial of an mRNA vaccine for seasonal influenza. The initiation of the study puts the partners ahead of Moderna and Pfizer in the race to show mRNA vaccines are as good or better at preventing flu than existing technologies. read more |
| |
|---|
|
| | Webinar: Five Common Mistakes in Panel Management Wednesday, July 14, 2021 | 1pm ET / 10am PT It takes time and focus to keep your panel in good health. By learning common pitfalls, this webinar will assist you in refining your panel management strategy and best practices to keep your respondents motivated and engaged. Register now. |
Top Stories By Nick Paul Taylor Blackstone Life Sciences, Cellex Cell Professionals and Intellia Therapeutics have teamed to create a CAR-T therapy startup. The biotech begins life with $250 million from Blackstone, universal CAR-T platforms from Cellex and CRISPR/Cas9 genome editing technology from Intellia. read more By Amirah Al Idrus After grabbing government grants to develop its polyclonal antibody treatment for COVID-19, SAB Biotherapeutics is going public through a $118 million SPAC merger. The proceeds will bankroll a pipeline of treatments for various diseases that are produced by and extracted from genetically modified cows. read more Sponsored by: Oracle Health Sciences In a recent virtual roundtable discussion, industry experts shared their insight on the challenges faced in implementing decentralized trials and how to address them. read more By Kyle LaHucik TRexBio is far from extinction as the discovery-stage biotech refuels with a new CEO and CMO and picks up Big Pharma backers. read more Sponsored by Alexion By refocusing company culture around the connection between employees and the rare disease community, Alexion has increased employee engagement and charted a new path for business success. Read more. read more By Annalee Armstrong After overseeing the $2.5 billion acquisition of Ra Pharmaceuticals last year, Douglas Treco, Ph.D., will lead Alchemab Therapeutics in its quest to develop therapies for hard-to-treat diseases. Treco is a well-connected executive with a history of raising biotechs up to be acquired by bigger pharmaceutical companies. read more By Conor Hale Insilico Medicine netted $255 million in its third investment round—a big step up from the $37 million it raised in 2019—reflecting what it’s achieved in the intervening years. read more Resources Sponsored by: Clinical Ink For faster deployment, improved patient engagement, and better-quality data — go where your patients are. GO BYOD with Lunexis™ from Clinical Ink. Sponsored by SDG Group Discover how Ashfield Healthcare uses the power of data and analytics to enable pre-call planning, inform sales rep actions and drive higher market share for its target pharmaceutical products. Sponsored by: BBK Worldwide Create a more diverse and inclusive clinical trial enrollment and engagement environment by learning the barriers to participation and the strategies to overcome them. Sponsored by: Thermo Fisher Scientific Autologous cell and gene therapy workflows involve isolating cells from an individual, engineering the cells, expanding and concentrating them, and infusing them back into the patient. Optimized automation of certain steps of the workflow may decrease hands-on time and the cost of the cell manufacturing process. Sponsored By: Veeva Learn how to develop a standards program that has your full team’s buy-in and improves the efficiency and quality of your clinical trials. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. Next Gen: What’s beyond the leading edge of biotech and pharma? June 22-23, 2021 | Virtual Event Biopharma Supply Chain June 29-30, 2021 | Virtual Event | 